Is Apomorphine registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 3 valid registrations of Apomorphine, including Dacepton (5 mg/ml, Solution for infusion, SAR 890.20); MOVAPO (5 mg/ml, Solution for infusion in cartridge, SAR 876.95); Movapo (10 mg/ml, Solution for injection, SAR 764.55).

Is Apomorphine approved by the US FDA?

Drugs@FDA lists 5 application product lines for Apomorphine, including APOKYN (Prescription); APOMORPHINE HYDROCHLORIDE (Prescription); ONAPGO (Prescription); APOKYN (Discontinued); KYNMOBI (Discontinued).

Is Apomorphine authorised in the European Union?

EMA lists 0 centrally authorised medicines containing Apomorphine.

Are there safety signals or safety updates for Apomorphine?

US FDA: 2 entries (latest 2022-09-22).

Active substance

Apomorphine

SFDA 3
US FDA 5
EMA 3
NHS prices 4
Safety 2

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
Dacepton	5 mg/ml	Solution for infusion · Subcutaneous use	5 Vial	SAR 890.20	NCE · Prescription	EVER Neuro Pharma GmbH	Valid
MOVAPO	5 mg/ml	Solution for infusion in cartridge · Subcutaneous use	5 Cartridge	SAR 876.95	NCE · Prescription	Britannia Pharmaceuticals Limited	Valid
Movapo	10 mg/ml	Solution for injection · Subcutaneous use	5 Pre-filled pen	SAR 764.55	NCE · Prescription	Britannia Pharmaceuticals Limited	Valid

Indications — CHI Daman Drug Formulary

ENDOMETRIOSIS; PARKINSONISM

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
APOKYN	30MG/3ML (10MG/ML)	injectable · subcutaneous	MDD US	Prescription	20 Apr 2004
APOMORPHINE HYDROCHLORIDE	30MG/3ML (10MG/ML)	injectable · subcutaneous	TP ANDA HOLDINGS	Prescription	23 Feb 2022
ONAPGO	98MG/20ML (4.9MG/ML)	solution · subcutaneous	MDD US	Prescription	3 Feb 2025
APOKYN	20MG/2ML (10MG/ML)	injectable · subcutaneous	MDD US	Discontinued	20 Apr 2004
KYNMOBI	10MG; 15MG; 20MG; 25MG; 30MG	film · sublingual	SUMITOMO PHARMA AM	Discontinued	21 May 2020

EMA European Union — centrally authorised medicines

Uprima Abbott Laboratories Ltd. · Withdrawn · authorised 28 May 2001 · ATC G04BE

Therapeutic indication (EMA)

Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.In order for Uprima to be effective, sexual stimulation is required.

Ixense Takeda Europe R Centre Ltd. · Withdrawn · authorised 28 May 2001 · ATC G04BE

Therapeutic indication (EMA)

Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.In order for Ixense to be effective, sexual stimulation is required.

Taluvian Abbott S.r.l. · Withdrawn · authorised 28 May 2001 · ATC G04BE

Therapeutic indication (EMA)

Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.In order for Taluvian to be effective, sexual stimulation is required.

Prices — United States and England

Source	Product as listed	Price	Unit / pack	Date
NHS Drug Tariff	Apomorphine 100mg/20ml solution for infusion vials	£145.00	5 vial	1 Oct 2026
NHS Drug Tariff	Apomorphine 30mg/3ml solution for injection cartridges	£123.00	5 cartridge	1 Oct 2026
NHS Drug Tariff	Apomorphine 30mg/3ml solution for injection pre-filled disposable devices	£123.91	5 pre-filled disposable injection	1 Oct 2026
NHS Drug Tariff	Apomorphine 50mg/10ml solution for infusion pre-filled syringes	£73.11	5 pre-filled disposable injection	1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Safety signals and safety-related labeling changes

US FDA 22 Sep 2022 KYNMOBI — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide
US FDA 22 Jun 2022 APOKYN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide

All safety entries for apomorphine →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.